Protagonist Therapeutics Inc Cash Flow Reinvestment Rate
Protagonist Therapeutics Inc cash flow reinvestment rate. Protagonist Therapeutics Inc (PTGX) has a Cash Flow Reinvestment Rate of 0.76x as of March 2025, reinvesting $94.95 Million (capex $545.00K plus investments $-94.40 Million) from operating cash flow of $125.36 Million. Explore PTGX debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Protagonist Therapeutics Inc (2017–2024)
Cash flow reinvestment rate of Protagonist Therapeutics Inc from 2017 to 2024. Historical reinvestment intensity for Protagonist Therapeutics Inc across 2 annual periods. Explore PTGX capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Protagonist Therapeutics Inc Cash Flow Reinvestment Rate by Year (2017–2024)
Protagonist Therapeutics Inc cash flow reinvestment rate by year from 2017 to 2024. Year-by-year capital reinvestment analysis for Protagonist Therapeutics Inc. For the full cash flow conversion analysis, see PTGX cash flow conversion.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.63x | $300.84 Million | $184.15 Million | $1.35 Million | ▼ -61.6% |
| 2017 | 4.26x | $16.49 Million | $3.87 Million | $666.00K | — |